-
公开(公告)号：US20140004198A1
公开(公告)日：2014-01-02
申请号：US13980166
申请日：2012-01-19
申请人： Per Balschmidt , Joern Drustrup , Kasper Huus
发明人： Per Balschmidt , Joern Drustrup , Kasper Huus
CPC分类号： A61K9/14 , A61K9/0019 , A61K9/143 , A61K9/146 , A61K9/5052 , A61K38/26 , A61K47/42
摘要： The present invention relates to compositions and particles comprising a GLP-1 compound, a divalent metal and a polycationic compound. The invention is characterised that the particle comprises a core and a surrounding layer, the core comprising the GLP-1 compound and the divalent metal, and the surrounding layer comprising the polycationic compound. The invention is particularly useful for the treatment of metabolic diseases, including diabetes.
摘要翻译： 本发明涉及包含GLP-1化合物，二价金属和聚阳离子化合物的组合物和颗粒。 本发明的特征在于，所述颗粒包含芯和周围层，所述芯包含GLP-1化合物和二价金属，并且包含聚阳离子化合物的周围层。 本发明特别可用于治疗包括糖尿病在内的代谢疾病。
-
公开(公告)号：US20140045754A1
公开(公告)日：2014-02-13
申请号：US13980147
申请日：2012-01-19
申请人： Joern Drustrup , Kasper Huus , Per Balschmidt
发明人： Joern Drustrup , Kasper Huus , Per Balschmidt
IPC分类号： A61K38/26
CPC分类号： A61K38/26 , A61K9/0019 , A61K9/08 , A61K9/10 , A61K47/02 , A61K47/186 , A61K47/42
摘要： The present invention relates to pharmaceutical compositions comprising a GLP-1 compound, a divalent metal and a polycationic compound. The invention is characterised in that the GLP-1:divalent metal molar ratio is 1:>2. The compositions of the invention are particularly useful in the treatment of diabetes.
摘要翻译： 本发明涉及包含GLP-1化合物，二价金属和聚阳离子化合物的药物组合物。 本发明的特征在于GLP-1：二价金属摩尔比为1:2。 本发明的组合物特别可用于治疗糖尿病。
-
3.发明申请公开(公告)号：US20060183197A1
公开(公告)日：2006-08-17
申请号：US10250800
申请日：2002-01-10
CPC分类号： C07K14/61
摘要： Conjugates exhibiting growth hormone (GH) activity and comprising at least one non-polypeptide moiety covalently attached to a GH polypeptide, the amino acid sequence of which differs from that of wildtype human GH in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule such as PEG or a sugar moiety. The conjugate finds particular use in therapy.
摘要翻译： 显示生长激素（GH）活性的缀合物并且包含共价连接到GH多肽的至少一个非多肽部分，所述多肽部分的氨基酸序列与至少一个引入的和至少一个去除的氨基酸残基中的野生型人GH的氨基酸序列不同 包含所述第一非多肽部分的连接基团。 第一非多肽部分是例如。 聚合物分子如PEG或糖部分。 该缀合物在治疗中特别有用。
-
公开(公告)号：US20090030183A1
公开(公告)日：2009-01-29
申请号：US12206275
申请日：2008-09-08
申请人： Poul Baad Rasmussen , Joern Drustrup , Grethe Rasmussen , Anders Hjelholt Pedersen , Hans Thalsgard Schambye , Kim Vilbour Andersen , Claus Bornaes
发明人： Poul Baad Rasmussen , Joern Drustrup , Grethe Rasmussen , Anders Hjelholt Pedersen , Hans Thalsgard Schambye , Kim Vilbour Andersen , Claus Bornaes
IPC分类号： C07K14/565 , C12P21/02 , C12N15/19 , C12N5/10 , C12N15/85
CPC分类号： A61K9/0019 , A61K9/0073 , A61K31/724 , A61K38/21 , A61K38/215 , A61K47/40 , A61K47/60 , A61K47/6951 , B82Y5/00 , C07K14/565 , A61K2300/00
摘要： The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.
摘要翻译： 本发明涉及一种表现出干扰素β（IFNB）活性的缀合物，其包含共价连接到IFNB多肽的至少一个第一非多肽部分，所述第一非多肽部分与至少一个引入的和在 至少一个除去的氨基酸残基，其包含所述第一非多肽部分的连接基团。 第一非多肽部分是例如。 聚合物分子或糖部分。 该缀合物在治疗中特别有用。 本发明还涉及包含至少一个体内糖基化位点的母体IFNB多肽的糖基化变体，其中位于所述糖基化位点附近的所述亲本多肽的氨基酸残基已被修饰以获得具有增加的糖基化的变体多肽作为 与母体多肽的糖基化相比。
-
-
-
搜索结果
4 条记录 (耗时 0.014 秒)
